Cardiac Events Associated With Chimeric Antigen Receptor T-Cells (CAR-T): A VigiBase Perspective.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

20 citing papers in PubMed.

1. Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.Current oncology reports · 2026
   Review
2. Mapping the evolution of cell and gene therapy product research: trends, collaborations, and emerging frontiers.Therapeutic innovation & regulatory science · 2026
   Review
3. Global Burden of Drug-Induced Anaphylaxis Associated With 33 Classes of Antibiotics (1968-2024): A Pharmacovigilance Analysis.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025
   Article
4. Post-marketing Safety Assessment of CAR T-cell Therapies: Analysis of Individual Case Safety Reports in the VigiBase.Therapeutic innovation & regulatory science · 2025
   Article
5. Cardiometabolic disease and cardio-oncology: Insights from iPSC models and tissue engineering.Cell reports. Medicine · 2025
   Review
6. Update on preclinical models of cancer therapy-related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio-Oncology, and the ESC Working Group on Cellular Biology of the Heart.European journal of heart failure · 2025
   Review
7. Role of Cardio-Oncology Rehabilitation in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell (CAR-T) Therapy.Circulation reports · 2025
   Review
8. Influence of CAR T-cell therapy associated complications.Frontiers in oncology · 2025
   Review
9. Cardiotoxic profiles of CAR-T therapy and bispecific T-cell engagers in hematological cancers.Communications medicine · 2024
   Article
10. Update on Immunotherapy Cardiotoxicity: Checkpoint Inhibitors, CAR T, and Beyond.Current treatment options in oncology · 2023
    Review
11. The broad spectrum of cardiotoxicities from immunotherapies.Frontiers in cardiovascular medicine · 2023
    Article
12. Chimeric antigen receptor-T cell therapy-related cardiotoxicity in adults and children cancer patients: A clinical appraisal.Frontiers in cardiovascular medicine · 2023
    Review
13. Case report: CAR-T cell therapy-induced cardiac tamponade.Frontiers in cardiovascular medicine · 2023
    Article
14. Cardiotoxicity of T-Cell Antineoplastic Therapies:JACC. CardioOncology · 2022
    Review
15. Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer.Nature reviews. Cardiology · 2022
    Review
16. Comparative safety of mRNA COVID-19 vaccines to influenza vaccines: A pharmacovigilance analysis using WHO international database.Journal of medical virology · 2022
    Article
17. Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database.Clinical and translational science · 2022
    Article
18. Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy.Journal of the American College of Cardiology · 2021
    Article
19. Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies.Circulation research · 2021
    Review
20. Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms.The Journal of clinical investigation · 2021
    Review

Corrections and comments

• Commented on by
  Reply: Cardiac Events Associated With Chimeric Antigen Receptor T Cells (CAR-T): A VigiBase Perspective.2020
• Comment on
  Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T).2019

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as